TransMedics Group Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? TransMedics Group Inc trades at $89.45 (market cap $3.07B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.43. Which is the better fit depends on your goals.
| TMDX | XDTE | |
|---|---|---|
Market Cap | $3.07B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $150.42 | $44.76 |
52-Week Low | $61.99 | $36.00 |
Enterprise Value | $3.46B | — |
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.
Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.
XDTE trades at $39.46, up 0.65% with bullish technical signals from moving averages. The ETF generates weekly dividend distributions but faces scrutiny over yield sustainability and NAV erosion despite S&P 500 highs. Recent coverage highlights structural concerns about whether distributions represent true income or return of capital.
The fund offers high weekly income but carries significant risks including potential capital erosion and tax inefficiency. While technical momentum appears positive, fundamental concerns about the covered call strategy's long-term viability warrant caution for income-focused investors seeking sustainable returns.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →